June 17th 2022
investor updates
For a copy of this analyst report please contact your CLSA advisor
June 7th 2022
analyst reports
June 7th 2022
analyst reports
June 6th 2022
analyst reports
June 6th 2022
analyst reports
June 4th 2022
press releases
Upcoming Events
What's next.
passion.
It takes a great deal of passion to pursue the fight against cancer and autoimmune diseases. We put our heart and soul into winning it.
know-how.
Our goal is to gather the strongest forces, the brightest minds and the most dedicated employees.
research.
Accurate research and development is the strongest foundation for developing effective treatments.
What is LAG-3?
Lymphocyte-activation gene 3, or LAG-3 (LAG-3), is a gene that provides the genetic information to make a cell surface molecule with biologic effects on T cell function.
LAG-3 is being used for many immunotherapy treatments including Eftilagimod Alpha from Immutep.
